Business Description
DiaMedica Therapeutics Inc
NAICS : 325410
SIC : 3741
ISIN : CA25253X1087
Total Employee Number:
35Description
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 235.16 | |||||
Equity-to-Asset | 0.85 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -11.4 | |||||
3-Year EPS without NRI Growth Rate | -10.4 | |||||
3-Year FCF Growth Rate | -12.2 | |||||
3-Year Book Growth Rate | -4.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -8.32 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 60.53 | |||||
9-Day RSI | 53.83 | |||||
14-Day RSI | 51.43 | |||||
3-1 Month Momentum % | 10.49 | |||||
6-1 Month Momentum % | -15.22 | |||||
12-1 Month Momentum % | 12.71 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.72 | |||||
Quick Ratio | 6.72 | |||||
Cash Ratio | 6.6 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -26.7 | |||||
Shareholder Yield % | 0.03 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -85.14 | |||||
ROA % | -75.7 | |||||
ROIC % | -2239.95 | |||||
3-Year ROIIC % | -2174.41 | |||||
ROC (Joel Greenblatt) % | -11509.98 | |||||
ROCE % | -88.7 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 9.06 | |||||
Price-to-Tangible-Book | 9.06 | |||||
EV-to-EBIT | -7.74 | |||||
EV-to-EBITDA | -7.75 | |||||
EV-to-Forward-Revenue | 32 | |||||
EV-to-FCF | -9.62 | |||||
| Price-to-Net-Current-Asset-Value | 9.16 | |||||
| Price-to-Net-Cash | 9.43 | |||||
Earnings Yield (Greenblatt) % | -12.92 | |||||
FCF Yield % | -9.1 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:DMAC
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
DiaMedica Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.72 | ||
| Beta | 1.7605 | ||
| 3-Year Sharpe Ratio | 0.59 | ||
| 3-Year Sortino Ratio | 0.94 | ||
| Volatility % | 54.37 | ||
| 14-Day RSI | 51.43 | ||
| 14-Day ATR ($) | 0.318124 | ||
| 20-Day SMA ($) | 6.65775 | ||
| 12-1 Month Momentum % | 12.71 | ||
| 52-Week Range ($) | 5.14 - 10.4195 | ||
| Shares Outstanding (Mil) | 53.93 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
DiaMedica Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
DiaMedica Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-13 08:00 | In 78 days | ||
| Third quarter earnings results for 2026 | 2026-11-12 | In 76 days | ||
| Guidance call for 2026 | 2026-09-09 | In 12 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-11 08:00 | 6.65 (+0.15%) | ||
| Second quarter earnings results for 2026 | 2026-08-10 | 6.75 (-1.46%) | ||
| Jefferies Global Healthcare Conference | 2026-06-02 | 5.84 (-2.01%) | ||
| General meeting for 2026 | 2026-05-20 09:00 | 5.57 (-1.94%) | ||
| Guidance call for 2026 | 2026-05-19 | 5.68 (-6.12%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 08:00 | 6.52 (+2.84%) | ||
| First quarter earnings results for 2026 | 2026-05-06 | 6.25 (+1.79%) |
Show
Entries
DiaMedica Therapeutics Inc Frequently Asked Questions
What is DiaMedica Therapeutics Inc(DMAC)'s stock price today?
The current price of DMAC is $6.43. The 52 week high of DMAC is $10.42 and 52 week low is $5.14.
When is next earnings date of DiaMedica Therapeutics Inc(DMAC)?
The next earnings date of DiaMedica Therapeutics Inc(DMAC) is 2026-11-12 Est..
Does DiaMedica Therapeutics Inc(DMAC) pay dividends? If so, how much?
DiaMedica Therapeutics Inc(DMAC) does not pay dividend.
Guru Commentaries on NAS:DMAC
Q2'26 Letter
Bullish
2026 Q2
Q2'26+letter
What the manager wrote
DiaMedica Therapeutics (DMAC) presents a compelling investment opportunity due to its innovative DM199 therapy, which targets critical blood flow issues in stroke and preeclampsia. The company has a strong foundation with promising clinical data, including a Phase 2 trial that shows significant improvement in non-MT stroke patients. The potential market for stroke treatment is estimated at $10 billion, while preeclampsia represents a $5 billion opportunity. DMAC's unique recombinant KLK1 protein can be produced to high standards without human sourcing, enhancing its appeal. With a solid cash position and no debt, DMAC is well-positioned for upcoming clinical milestones, making it an attractive addition to our portfolio.
Press Release
Articles on DiaMedica Therapeutics Inc
DiaMedica Therapeutics (DMAC) Reports Positive Interim Data, Market Pricing Reflects High Growth Expectations
Aug 10, 2026
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers